LUC00101I1 - - Google Patents
Info
- Publication number
- LUC00101I1 LUC00101I1 LUC00101C LUC00101I1 LU C00101 I1 LUC00101 I1 LU C00101I1 LU C00101 C LUC00101 C LU C00101C LU C00101 I1 LUC00101 I1 LU C00101I1
- Authority
- LU
- Luxembourg
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23807309P | 2009-08-28 | 2009-08-28 | |
US31303910P | 2010-03-11 | 2010-03-11 | |
PCT/US2010/046930 WO2011025927A1 (fr) | 2009-08-28 | 2010-08-27 | Composés et compositions en tant qu'inhibiteurs de protéine kinase |
Publications (2)
Publication Number | Publication Date |
---|---|
LUC00101I1 true LUC00101I1 (fr) | 2019-02-13 |
LUC00101I2 LUC00101I2 (fr) | 2020-01-23 |
Family
ID=42782253
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU00101C LUC00101I2 (fr) | 2009-08-28 | 2019-02-12 | |
LU00102C LUC00102I2 (fr) | 2009-08-28 | 2019-02-12 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU00102C LUC00102I2 (fr) | 2009-08-28 | 2019-02-12 |
Country Status (50)
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
ES2674682T3 (es) | 2010-02-25 | 2018-07-03 | Dana-Farber Cancer Institute, Inc. | Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF |
US8907270B2 (en) | 2010-06-30 | 2014-12-09 | Schlumberger Technology Corporation | Method and apparatus for gain regulation in a gamma detector |
CN108542906A (zh) * | 2011-11-11 | 2018-09-18 | 诺华股份有限公司 | 治疗增生性疾病的方法 |
JP6216325B2 (ja) * | 2011-11-23 | 2017-10-18 | ノバルティス アーゲー | 医薬製剤 |
US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
CN103159736B (zh) * | 2011-12-10 | 2015-05-13 | 通化济达医药有限公司 | 取代的吡唑激酶抑制剂 |
TW201332989A (zh) * | 2011-12-23 | 2013-08-16 | Millennium Pharm Inc | 雜芳基化合物及其用途 |
ES2673070T3 (es) | 2012-03-28 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Mutantes C-RAF que confieren resistencia a los inhibidores de RAF |
WO2014015054A1 (fr) | 2012-07-18 | 2014-01-23 | Saint Louis University | Dérivés d'acides bêta aminés en tant qu'antagonistes d'intégrine |
US8716226B2 (en) | 2012-07-18 | 2014-05-06 | Saint Louis University | 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists |
AR091876A1 (es) * | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
LT2882440T (lt) | 2012-08-07 | 2019-04-25 | Novartis Ag | Farmaciniai deriniai, apimantys b-raf slopiklį, egfr slopiklį ir nebūtinai pi3k-alfa slopiklį |
SG10201708494QA (en) | 2012-08-17 | 2017-11-29 | Hoffmann La Roche | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
WO2014047330A1 (fr) * | 2012-09-19 | 2014-03-27 | Jean-Michel Vernier | Nouveaux inhibiteurs de raf kinase |
JP2015536964A (ja) | 2012-11-08 | 2015-12-24 | ノバルティス アーゲー | B−raf阻害剤とヒストン脱アセチル化酵素阻害剤を含む医薬組合せおよび増殖性疾患の治療におけるそれらの使用 |
SG10201906270VA (en) | 2013-03-21 | 2019-08-27 | Novartis Ag | Combination therapy comprising a b-raf inhibitor and a second inhibitor |
TWI634114B (zh) * | 2013-05-08 | 2018-09-01 | 永恒生物科技公司 | 作為激酶抑制劑之呋喃酮化合物 |
BR112015028845A2 (pt) | 2013-05-30 | 2017-07-25 | Plexxikon Inc | compostos para a modulação da quinase e indicações da mesma |
EP3049442A4 (fr) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Méthodes de traitement de cancers hématologiques |
WO2015084804A1 (fr) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combinaison d'un inhibiteur de mdm2 et d'un inhibiteur de braf, et leur utilisation |
JP6678585B2 (ja) * | 2013-12-20 | 2020-04-22 | バイオメッド バレー ディスカバリーズ,インコーポレイティド | Erk阻害剤およびraf阻害剤の組み合わせを使用するがん処置 |
BR112016012506A8 (pt) * | 2013-12-23 | 2018-01-30 | Novartis Ag | combinações farmacêuticas, seus usos, e uso de um portador de dados |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
DE102015103158A1 (de) | 2014-03-04 | 2015-09-10 | Bergische Universität Wuppertal | Verbindungen für die Behandlung des Melanoms |
CR20160425A (es) | 2014-03-14 | 2017-05-26 | Novartis Ag | Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas |
WO2015145388A2 (fr) | 2014-03-27 | 2015-10-01 | Novartis Ag | Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt |
WO2015175846A2 (fr) * | 2014-05-16 | 2015-11-19 | University Of Massachusetts | Traitement de la leucémie myéloïde chronique (lmc) |
WO2016038582A1 (fr) * | 2014-09-12 | 2016-03-17 | Novartis Ag | Composés et compositions comme inhibiteurs de protéines kinases |
CN107206071A (zh) | 2014-09-13 | 2017-09-26 | 诺华股份有限公司 | Alk抑制剂的联合疗法 |
US20170209574A1 (en) | 2014-10-03 | 2017-07-27 | Novartis Ag | Combination therapies |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
ES2952717T3 (es) | 2014-10-14 | 2023-11-03 | Novartis Ag | Moléculas de anticuerpos contra PD-L1 y usos de las mismas |
MY190404A (en) | 2015-03-10 | 2022-04-21 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
WO2017019897A1 (fr) | 2015-07-29 | 2017-02-02 | Novartis Ag | Polythérapies comprenant des molécules d'anticorps contre tim -3 |
LT3317301T (lt) | 2015-07-29 | 2021-07-26 | Novartis Ag | Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3 |
CN114272371A (zh) | 2015-07-29 | 2022-04-05 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
BR112018008891A8 (pt) | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos |
EP3389712B1 (fr) | 2015-12-17 | 2024-04-10 | Novartis AG | Molécules d'anticorps anti-pd-1 et leurs utilisations |
ES2806276T3 (es) | 2015-12-30 | 2021-02-17 | Univ Saint Louis | Derivados de ácido aminobenzoico meta-azaciclicos como antagonistas pan-integrina |
RU2615986C1 (ru) * | 2016-02-25 | 2017-04-12 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения |
PT3463345T (pt) * | 2016-06-03 | 2023-01-06 | Array Biopharma Inc | Combinações farmacêuticas |
WO2018009466A1 (fr) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations |
EP3564232B1 (fr) * | 2016-12-27 | 2022-01-26 | Riken | Composé inhibiteur de signal bmp |
WO2018146253A1 (fr) | 2017-02-10 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions pharmaceutiques pour le traitement de cancers associés à l'activation de la voie mapk |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
CN107540699A (zh) * | 2017-10-16 | 2018-01-05 | 康化(上海)新药研发有限公司 | 一种2‑氨基‑3‑氟吡啶‑4‑硼酸盐酸盐的合成方法 |
CA3086765A1 (fr) | 2017-12-28 | 2019-07-04 | Tract Pharmaceuticals, Inc. | Systemes de culture de cellules souches pour cellules souches epitheliales colonnaires, et leurs utilisations |
EP3816162A4 (fr) * | 2018-07-12 | 2021-08-11 | Shenzhen TargetRx, Inc. | Composé diarylpyrazole, composition le comprenant et utilisation associée |
WO2020124397A1 (fr) * | 2018-12-19 | 2020-06-25 | Inventisbio Shanghai Ltd. | Inhibiteurs de kinase src c-terminale |
EP3903828A4 (fr) | 2018-12-21 | 2022-10-05 | Daiichi Sankyo Company, Limited | Combinaison d'un conjugué anticorps-médicament et d'un inhibiteur de kinase |
WO2020231976A1 (fr) | 2019-05-16 | 2020-11-19 | Eli Lilly And Company | Triple association d'un inhibiteur d'erk1/2, d'un inhibiteur de braf et d'un inhibiteur de l'egfr, destinée à être utilisée dans le traitement du cancer colorectal positif pour la mutation v600e de braf |
CN114746419B (zh) | 2019-12-05 | 2023-10-24 | 国家医疗保健研究所 | N-(3-(5-(嘧啶-4-基)噻唑-4-基)苯基)磺酰胺化合物及其用作braf抑制剂的用途 |
US20230303551A1 (en) | 2020-08-13 | 2023-09-28 | Albert Einstein College Of Medicine | N-cyclyl-sulfonamides useful for inhibiting raf |
WO2022074011A1 (fr) | 2020-10-05 | 2022-04-14 | Pierre Fabre Medicament | Association d'encorafénib et de binimétinib comme traitement adjuvant pour un mélanome de stade ii réséqué |
CN117321418A (zh) | 2021-03-18 | 2023-12-29 | 诺华股份有限公司 | 癌症生物标志物及其使用方法 |
IL307964A (en) | 2021-06-09 | 2023-12-01 | Chugai Pharmaceutical Co Ltd | Combined treatment for cancer |
CN114181197B (zh) * | 2022-02-16 | 2022-05-06 | 北京康立生医药技术开发有限公司 | 一种治疗肠癌的药物的制备方法、制剂及纯度分析方法 |
WO2023230554A1 (fr) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combinaison d'un inhibiteur de braf, d'un inhibiteur d'egfr et d'un antagoniste de pd-1 pour le traitement du cancer colorectal msi-h/dmmr, avec mutation v600e de braf |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4104250A (en) * | 1976-08-11 | 1978-08-01 | Borg-Warner Corporation | Flame-retardant polymers with 1,3,5-triazines having halo- and halo-aryl substitutents |
JPS5475888A (en) | 1977-11-29 | 1979-06-18 | Jiyasuko Kk | Surgical laser |
EP0184384B1 (fr) | 1984-12-06 | 1989-08-02 | Pfizer Inc. | Acides dihydroquinolonecarboxyliques substitués et compositions antibactériennes les contenant |
US6391636B1 (en) | 1994-05-31 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
US6358932B1 (en) | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
US6037136A (en) | 1994-10-24 | 2000-03-14 | Cold Spring Harbor Laboratory | Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto |
JPH11514979A (ja) | 1995-09-07 | 1999-12-21 | フイズ テクノロジーズ リミテッド | 実質的に非溶解性の生体作用薬剤をバイオ・アベイラブルにするシステム |
US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
WO1997044058A1 (fr) | 1996-05-23 | 1997-11-27 | Applied Research Systems Ars Holding N.V. | Composes inhibant la liaison de proteines raf-1 ou 14-3-3 a la chaine beta du recepteur d'il-2, et compositions pharmaceutiques les contenant |
AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
BR9809147A (pt) | 1997-05-22 | 2000-08-01 | Searle & Co | Composto pirazol substituìdo, composição farmacêutica, processos para tratar um distúrbio mediado por tnf, um distúrbio mediado por quinase p38, inflamação e artrite, e, para preparar pirazóis |
US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
US6204467B1 (en) | 1998-03-24 | 2001-03-20 | Ford Global Technologies, Inc. | Method and apparatus for resistive welding |
RU2319693C9 (ru) | 1999-01-13 | 2008-08-20 | Байер Копэрейшн | Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты) |
US6316435B2 (en) | 1999-02-24 | 2001-11-13 | Supergen, Inc. | Combination therapy for lymphoproliferative diseases |
CA2396380C (fr) | 1999-12-23 | 2015-04-21 | David Hayes | Compositions pharmaceutiques ameliorees pour medicaments peu solubles |
AU2001285349A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The University Of Arkansas | Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2 |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
PT1441714E (pt) | 2001-10-25 | 2008-03-10 | Novartis Ag | Combinações compreendendo um inibidor selectivo da ciclo-oxigenase 2 |
ATE374753T1 (de) | 2001-12-21 | 2007-10-15 | Vernalis Cambridge Ltd | 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung |
CN101486682B (zh) | 2002-03-13 | 2013-08-14 | 阵列生物制药公司 | 作为mek抑制剂的n3烷基化苯并咪唑衍生物 |
US20080085902A1 (en) | 2003-09-23 | 2008-04-10 | Guido Bold | Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent |
JP5095216B2 (ja) | 2003-11-14 | 2012-12-12 | ローラス セラピューティクス インコーポレーテッド | アリールイミダゾールおよびその抗癌剤としての使用 |
EP1706400A1 (fr) | 2004-01-09 | 2006-10-04 | Novartis AG | Derives de phenyl- 4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl¨-amine utilises comme inhibiteurs du recepteur igf-1r |
US7745437B2 (en) | 2004-06-10 | 2010-06-29 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
MX2007011435A (es) | 2005-03-17 | 2007-12-05 | Novartis Ag | N-[3-(1-amino-5,6,7,8-tetrahidro-2,4,4b-triazafluoren-9-il)-fenil ]-benzamidas como inhibidores de cinasa de tirosina/treonina, en particular de cinasa b-raf. |
US20070099856A1 (en) | 2005-05-13 | 2007-05-03 | Gumerlock Paul H | Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen |
WO2007021966A1 (fr) | 2005-08-12 | 2007-02-22 | Synta Pharmaceuticals Corp. | Composes pyrazoles modulant l'activite de la proteine hsp90 |
CA2619035A1 (fr) | 2005-08-22 | 2007-03-01 | Novartis Ag | Compositions pharmaceutiques |
WO2007024843A2 (fr) | 2005-08-26 | 2007-03-01 | Smithkline Beecham Corporation | Inhibiteurs de pyrimidinyl-pyrazole d'aurora kinases |
TWI387592B (zh) | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
WO2007105058A2 (fr) | 2006-03-16 | 2007-09-20 | Pfizer Products Inc. | Pyrazoles |
AU2007234379A1 (en) | 2006-04-05 | 2007-10-11 | Novartis Ag. | Combinations of therapeutic agents for treating cancer |
US7501430B2 (en) * | 2006-04-17 | 2009-03-10 | Arqule, Inc. | RAF inhibitors and their uses |
US20080221132A1 (en) | 2006-09-11 | 2008-09-11 | Xiong Cai | Multi-Functional Small Molecules as Anti-Proliferative Agents |
AU2007299080B2 (en) | 2006-09-18 | 2013-04-18 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring EGFR mutations |
CN103739595A (zh) | 2006-10-02 | 2014-04-23 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
AU2007308045A1 (en) * | 2006-10-06 | 2008-04-17 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
EP2491923A3 (fr) | 2007-02-15 | 2012-12-26 | Novartis AG | Combinaisons d'agents thérapeutiques pour traiter le cancer |
US20090022789A1 (en) | 2007-07-18 | 2009-01-22 | Supernus Pharmaceuticals, Inc. | Enhanced formulations of lamotrigine |
BRPI0815042A2 (pt) * | 2007-08-01 | 2015-02-10 | Pfizer | Compostos de pirazol |
CN101827584A (zh) | 2007-10-19 | 2010-09-08 | 雅培股份有限两合公司 | N-芳基脲基药物的固态分散体产品 |
CA2704436C (fr) | 2007-11-14 | 2016-01-05 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Derives imidazo[1,2-a]pyridine et leur utilisation comme modulateurs allosteriques positifs des recepteurs mglur2 |
US8129394B2 (en) * | 2008-03-21 | 2012-03-06 | Novartis Ag | Heteroaryl-substituted imidazole compounds and uses thereof |
UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
EA019722B1 (ru) | 2008-07-24 | 2014-05-30 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ |
EP2326622A1 (fr) | 2008-07-28 | 2011-06-01 | Gilead Sciences, Inc. | Composés inhibiteurs de cycloalkylidène et d'hétérocycloalkylidène d'histone désacétylase |
PE20110294A1 (es) | 2008-09-29 | 2011-05-26 | Boehringer Ingelheim Int | Compuestos heterociclicos como inhibidores de enzimas de senal especifica |
HRP20161154T4 (hr) | 2008-10-07 | 2023-09-29 | Kudos Pharmaceuticals Limited | Farmaceutska formulacija 514 |
WO2010056662A1 (fr) * | 2008-11-11 | 2010-05-20 | University Of Washington | Signalisation de wnt-bêta-caténine dans le mélanome |
ES2422263T3 (es) | 2008-12-19 | 2013-09-10 | Nerviano Medical Sciences Srl | Pirazoles bicíclicos como inhibidores de la proteinquinasa |
AR075180A1 (es) | 2009-01-29 | 2011-03-16 | Novartis Ag | Formulaciones orales solidas de una pirido-pirimidinona |
RU2402602C1 (ru) | 2009-02-12 | 2010-10-27 | Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН | КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН |
WO2010100127A1 (fr) | 2009-03-04 | 2010-09-10 | Novartis Ag | Dérivés d'imidazole disubstitués en tant que modulateurs de la protéine kinase raf |
TWI532484B (zh) | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
US8546413B2 (en) * | 2009-06-15 | 2013-10-01 | Nerviano Medical Sciences S.R.L. | Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors |
KR101256018B1 (ko) * | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
US8242260B2 (en) * | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
AU2011209234B2 (en) | 2010-01-27 | 2015-05-07 | Nerviano Medical Sciences S.R.L. | Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors |
NZ718622A (en) | 2010-03-30 | 2018-03-23 | Verseon Corp | Multisubstituted aromatic compounds as inhibitors of thrombin |
EP2601185B1 (fr) | 2010-08-03 | 2015-10-07 | Nerviano Medical Sciences S.r.l. | Dérivés de composés de pyrazolophényl-benzènesulfonamide et leur utilisation en tant qu'agents antitumoraux |
PL2688572T3 (pl) | 2011-03-21 | 2017-08-31 | Valcuria Ab | Kompozycja farmaceutyczna zawierająca inhibitor hdac i steroid oraz jej stosowanie |
BR112013032125A2 (pt) | 2011-06-14 | 2016-12-13 | Novartis Ag | combinação de panobinostat e ruxolitinibe no tratamento de câncer do tipo neoplasia mieloproliferativa |
CN108542906A (zh) | 2011-11-11 | 2018-09-18 | 诺华股份有限公司 | 治疗增生性疾病的方法 |
JP6216325B2 (ja) | 2011-11-23 | 2017-10-18 | ノバルティス アーゲー | 医薬製剤 |
JP2015536964A (ja) | 2012-11-08 | 2015-12-24 | ノバルティス アーゲー | B−raf阻害剤とヒストン脱アセチル化酵素阻害剤を含む医薬組合せおよび増殖性疾患の治療におけるそれらの使用 |
US10576680B2 (en) | 2015-11-19 | 2020-03-03 | The Boeing Company | Modular thermoforming system |
-
2010
- 2010-08-26 AR ARP100103123A patent/AR077975A1/es active IP Right Grant
- 2010-08-26 JO JOP/2010/0297A patent/JO3002B1/ar active
- 2010-08-27 PT PT141529453T patent/PT2727918T/pt unknown
- 2010-08-27 PL PL10748211T patent/PL2470526T3/pl unknown
- 2010-08-27 EA EA201500175A patent/EA201500175A1/ru unknown
- 2010-08-27 HU HUE14152945A patent/HUE032847T2/hu unknown
- 2010-08-27 KR KR1020127007860A patent/KR101413392B1/ko active IP Right Grant
- 2010-08-27 GE GEAP201012645A patent/GEP20146102B/en unknown
- 2010-08-27 CA CA2771775A patent/CA2771775C/fr active Active
- 2010-08-27 PE PE2012000268A patent/PE20120861A1/es active IP Right Grant
- 2010-08-27 SG SG10201405311TA patent/SG10201405311TA/en unknown
- 2010-08-27 CU CU2012000034A patent/CU24110B1/es active IP Right Grant
- 2010-08-27 RS RS20140430A patent/RS53489B1/en unknown
- 2010-08-27 EP EP14152945.3A patent/EP2727918B1/fr active Active
- 2010-08-27 NZ NZ598924A patent/NZ598924A/xx unknown
- 2010-08-27 ES ES14152945.3T patent/ES2610825T3/es active Active
- 2010-08-27 CN CN201410040923.XA patent/CN103896921B/zh active Active
- 2010-08-27 EP EP10748211.9A patent/EP2470526B1/fr active Active
- 2010-08-27 SI SI201030711T patent/SI2470526T1/sl unknown
- 2010-08-27 PT PT107482119T patent/PT2470526E/pt unknown
- 2010-08-27 RS RS20170017A patent/RS55568B1/sr unknown
- 2010-08-27 ME MEP-2017-6A patent/ME02684B/fr unknown
- 2010-08-27 UY UY0001032860A patent/UY32860A/es active IP Right Grant
- 2010-08-27 PL PL14152945T patent/PL2727918T3/pl unknown
- 2010-08-27 DK DK14152945.3T patent/DK2727918T3/da active
- 2010-08-27 SI SI201031371A patent/SI2727918T1/sl unknown
- 2010-08-27 SG SG2012009304A patent/SG178351A1/en unknown
- 2010-08-27 DK DK10748211.9T patent/DK2470526T3/da active
- 2010-08-27 ES ES10748211.9T patent/ES2492499T3/es active Active
- 2010-08-27 MY MYPI2012000611A patent/MY156259A/en unknown
- 2010-08-27 MX MX2012002546A patent/MX2012002546A/es active IP Right Grant
- 2010-08-27 ME MEP-2014-94A patent/ME01860B/me unknown
- 2010-08-27 UA UAA201203042A patent/UA112285C2/uk unknown
- 2010-08-27 BR BR112012004453-2A patent/BR112012004453B1/pt active IP Right Grant
- 2010-08-27 AU AU2010286569A patent/AU2010286569C1/en active Active
- 2010-08-27 CN CN201080038197.8A patent/CN102725283B/zh active Active
- 2010-08-27 JP JP2012527014A patent/JP5475888B2/ja active Active
- 2010-08-27 WO PCT/US2010/046930 patent/WO2011025927A1/fr active Application Filing
- 2010-08-27 LT LTEP14152945.3T patent/LT2727918T/lt unknown
- 2010-08-27 IN IN2469DEN2012 patent/IN2012DN02469A/en unknown
- 2010-08-27 US US12/870,130 patent/US8501758B2/en not_active Ceased
- 2010-08-27 EA EA201200373A patent/EA025222B1/ru not_active IP Right Cessation
-
2012
- 2012-02-09 CL CL2012000340A patent/CL2012000340A1/es unknown
- 2012-02-13 IL IL218084A patent/IL218084A/en active IP Right Grant
- 2012-02-17 TN TNP2012000081A patent/TN2012000081A1/en unknown
- 2012-02-24 NI NI201200029A patent/NI201200029A/es unknown
- 2012-02-24 CO CO12032570A patent/CO6612222A2/es active IP Right Grant
- 2012-02-24 DO DO2012000051A patent/DOP2012000051A/es unknown
- 2012-02-27 HN HN2012000441A patent/HN2012000441A/es unknown
- 2012-02-27 GT GT201200053A patent/GT201200053A/es unknown
- 2012-02-28 EC ECSP12011700 patent/ECSP12011700A/es unknown
- 2012-02-28 CR CR20120102A patent/CR20120102A/es unknown
- 2012-03-19 ZA ZA2012/02020A patent/ZA201202020B/en unknown
- 2012-03-23 MA MA34716A patent/MA33604B1/fr unknown
- 2012-08-15 HK HK12108012.3A patent/HK1167390A1/xx unknown
-
2013
- 2013-06-28 US US13/931,111 patent/US9314464B2/en active Active
-
2014
- 2014-02-06 JP JP2014021339A patent/JP6045519B2/ja active Active
- 2014-08-21 HR HRP20140799AT patent/HRP20140799T1/hr unknown
- 2014-09-12 SM SM201400133T patent/SMT201400133B/xx unknown
-
2016
- 2016-01-13 US US14/994,710 patent/US9593099B2/en active Active
- 2016-01-13 US US14/994,827 patent/US9593100B2/en active Active
- 2016-03-15 US US15/070,905 patent/US10005761B2/en active Active
- 2016-06-10 US US15/179,644 patent/US9850230B2/en active Active
- 2016-06-10 US US15/179,385 patent/US9850229B2/en active Active
-
2017
- 2017-01-03 HR HRP20170005TT patent/HRP20170005T1/hr unknown
- 2017-01-10 CY CY20171100028T patent/CY1118452T1/el unknown
- 2017-01-19 SM SM201700036T patent/SMT201700036B/it unknown
- 2017-11-20 US US15/818,082 patent/US10576080B2/en active Active
- 2017-11-20 US US15/818,264 patent/US10568884B2/en active Active
-
2019
- 2019-02-12 LU LU00101C patent/LUC00101I2/fr unknown
- 2019-02-12 LU LU00102C patent/LUC00102I2/fr unknown
- 2019-03-01 HU HUS1900012C patent/HUS1900012I1/hu unknown
- 2019-03-01 HU HUS1900013C patent/HUS1900013I1/hu unknown
- 2019-03-05 NO NO2019011C patent/NO2019011I1/no unknown
- 2019-03-07 LT LTPA2019005C patent/LTC2470526I2/lt unknown
- 2019-03-07 LT LTPA2019006C patent/LTPA2019006I1/lt unknown
- 2019-03-15 NL NL300973C patent/NL300973I2/nl unknown
- 2019-03-18 CY CY2019013C patent/CY2019013I2/el unknown
- 2019-03-18 CY CY2019014C patent/CY2019014I2/el unknown
-
2020
- 2020-01-14 US US16/741,937 patent/US20200323852A1/en not_active Abandoned
-
2021
- 2021-07-15 US US17/376,199 patent/USRE49556E1/en active Active
-
2022
- 2022-04-20 US US17/724,589 patent/US20230116233A1/en not_active Abandoned
-
2023
- 2023-01-27 EC ECSENADI20234573A patent/ECSP23004573A/es unknown